Oligonucleotide manufacturing translates a controlled molecular definition into hundreds of repeated chemical operations, then separates, pools, and transforms the resulting material into an API or drug substance. Sequence, position, chemistry, reagent identity, cycle performance, fractions, impurities, and mass balance must remain connected.
Seal represents ASO, siRNA, aptamer, guide RNA, and other synthetic oligonucleotide processes without reducing them to a generic chemical batch. The sequence becomes an executable manufacturing input and a persistent analytical reference.
The molecular definition is the manufacturing authority
The product definition includes nucleotide sequence and direction, strand role, length, backbone, sugar and base modifications, protecting groups, conjugates, counterion, salt form, structure, molecular formula and mass, quality attributes, impurity strategy, specifications, methods, stability, and regulatory state.
A rendered sequence is never the sole authority. Structured position-
Sequence approval is independent of batch creation
Draft, reviewed, approved, effective, superseded, and retired sequences retain author, checker, evidence, comparison, signatures, and intended products. Machine-readable import is reconciled with human-readable notation.
Changes highlight insertions, deletions, substitutions, modification changes, conjugate changes, and strand relationship. An active batch cannot resolve an unapproved molecular version.
Recipe generation is deterministic and reviewed
The effective sequence and chemistry generate cycle order, amidite position, coupling parameters, capping, oxidation or sulfurization, detritylation, wash, repeat logic, expected consumption, and instrument method. Generated output retains generator version, inputs, checksum, review, and approval.
Manual overrides are bounded fields with rationale and impact. The system compares the manufacturing recipe with the molecular definition before release.
Starting materials have position-specific purpose
Phosphoramidites, solid support, activators, capping reagents, oxidizers, sulfurization reagents, deblocking solutions, solvents, scavengers, cleavage and deprotection reagents, purification buffers, and conjugation materials retain lot, quality, concentration, water content or other critical attributes, storage, expiry, and status.
Issue records actual material and lot by cycle or operation. A later reagent alert can identify exact sequence positions, batches, fractions, and final lots exposed.
Synthesis captures cycle-level performance without drowning the batch
The synthesizer can remain authoritative for valve actions and high-frequency signals. Seal records cycle identity, intended base and modification, reagent lots, start and end, key parameters, detrityl or other monitoring response, alarms, holds, repeats, source file, and acceptance.
Exceptions retain the exact cycle and sequence position. A repeated coupling does not overwrite the initial event or silently shift the remaining sequence.
Equipment configuration is part of the synthesis state
Synthesizer, column or reactor, scale, lines, bottle positions, software, firmware, instrument method, calibration, maintenance, cleaning, and prior-product state are verified before start.
Line mapping reconciles physical reagent positions with the generated recipe. Changes during a run create controlled events and impact assessment.
Cleavage and deprotection create new chemical states
Resin or support identity, cleavage reagent, reaction conditions, time, temperature, mixing, washes, transfers, recovery, and deprotection conditions remain connected to the synthesis lot. Intermediate material receives its own identity, quantity, concentration, container, status, and hold.
One-pot, staged, solution-phase, and product-specific paths can be configured. Hazard and containment controls follow the actual chemistry.
Purification fractions are first-class material
Chromatography load, column and packing, method, buffers, gradients, detector signals, fractions, containers, volumes, concentrations, identity or purity tests, pooling decisions, regeneration, cleaning, and cycle state form one record.
Each fraction retains source and destination lineage. Discarded, reprocessed, held, pooled, and investigation fractions remain in the mass balance.
Pooling is a scientific and quantity decision
The pool plan defines eligible fractions and preliminary criteria. Actual inclusion or exclusion records purity, identity, impurity profile, concentration, volume, quantity contribution, rationale, reviewer, and resulting pool calculation.
Many-to-one genealogy supports backward tracing from final API to exact chromatographic intervals and forward tracing from a concerning fraction to every derived container.
Conjugation and duplexing preserve component stoichiometry
Ligand conjugation, linker activation, coupling, quench, purification, and residual removal connect conjugate lots, stoichiometry, conditions, yields, samples, and analytical evidence.
For siRNA and other multi-strand products, sense and antisense lineages remain separate through manufacture and release, then converge at annealing or duplexing with molar ratio, mixing, temperature profile, hold, confirmation, and final identity.
Ultrafiltration, desalting, and counterion exchange track exposure
Membrane or cassette identity, lot, configuration, integrity, load, cycles, volumes, diafiltration exchanges, conductivity, pH, concentration, yields, holds, and samples remain connected to the pool.
Solvent and counterion transitions create explicit material states. Units and basis—mass, moles, nucleotide equivalents, solution volume, or dry content—remain clear.
Drying and final API handling preserve quantity basis
Lyophilization, precipitation, drying, milling where used, sieving, subdivision, and packaging record equipment, recipe, containers, conditions, yields, samples, environment, and exposure. Gross, tare, net, dry-content corrected, and assay-corrected quantities are distinguishable.
Final containers retain identity, quantity, storage, label, sampling, status, and use or shipment genealogy.
Identity, assay, purity, full-length product, deletion and addition sequences, truncated species, oxidation, depurination, protecting-group residuals, conjugate-related species, residual solvents, water, counterion, bioburden, endotoxin, and other attributes attach to exact stages.
Methods retain sample preparation, instrument, sequence reference, impurity nomenclature, standards, source data, peak integration or deconvolution, calculation, specification, and review. A peak name remains traceable to the molecular and method versions that define it.
Mass balance uses chemistry-aware quantities
The batch reconciles theoretical loading, nucleotide equivalents, reagent use, crude recovery, fraction quantities, pooled amount, process losses, samples, rework, waste, dry content, assay correction, final containers, and yield.
Differences in molar and mass basis are explicit. Manual conversions use versioned formulas, source values, units, precision, and review.
Holds, storage, and solution age are enforced
Amidite and reagent open life, synthesis interruption, cleavage and deprotection holds, crude storage, fraction age, pool hold, conjugation intermediate, duplex, bulk solution, and dried API each use defined clock and environmental conditions.
Approaching limits inform scheduling. Excursions attach to affected containers and downstream material rather than remaining an isolated equipment alarm.
Cleaning and campaign control address product carryover
Shared synthesizers, lines, columns, tanks, dryers, and tools retain product-contact history, cleaning procedure, residue target, limits, samples, results, inspection, and release. Sequence- or chemistry-specific worst cases can influence validation and campaign order.
Potent conjugates and novel modifications can introduce dedicated containment, segregation, or deactivation requirements. The equipment state gates the next product.
Release joins sequence, process, purity, and quantity evidence
Disposition reconciles molecular version, raw materials, generated recipe, cycle evidence, equipment, cleavage and deprotection, purification fractions, pool rationale, conjugation or duplexing, final processing, analytical results, mass balance, holds, deviations, cleaning, containers, and stability obligations.
The European Medicines Agency's guideline on development and manufacture of oligonucleotides addresses the modality's specific CMC considerations. Seal organizes executable evidence while the manufacturer's process and control strategy remain authoritative.
Prove one sequence-to-container lineage
The first implementation should follow one modified sequence from approval through deterministic recipe generation, material issue by position, synthesis cycles, a repeated coupling, cleavage and deprotection, chromatography, fraction testing, pool selection, ultrafiltration, lyophilization, impurity analysis, mass balance, containerization, and release.
Include a wrong bottle-position scan, low coupling response, instrument-data gap, out-of-hold crude, borderline fraction, pool amendment, membrane-integrity failure, impurity integration change, assay-corrected quantity discrepancy, and post-release amidite alert. The model is ready when a final container can reconstruct every base, cycle, fraction, and decision.
